JERUSALEM — Teva Pharmaceutical Industries Ltd. has launched amlodipine/valsartan/hydrochlorothiazide tablets, a hypertension medication, in the United States.
Teva said Monday that its product is a generic equivalent of Exforge HCT tablets from Novartis.
In addition, Teva reported that it was first-to-file, opening the generic market for the product and making it eligible for 180 days of marketing exclusivity.
Exforge HCT had annual U.S. sales of about $158 million in the United States through September, according to IMS Health data cited by Teva.
Exforge HCT is used to treat high blood pressure and is typically prescribed when other hypertension medications haven’t been successful in treatment.
